An Activist FDA Could Benefit Drug Development
This article was originally published in RPM Report
Executive Summary
Former FDA Commissioner David Kessler sees a big opportunity for FDA to clarify approval criteria for cancer drugs and personalized medicine projects in the period after the upcoming election. This is time to begin planning for that period of opportunity.
You may also be interested in...
Accelerated Approval Does Not Speed Oncologics To Market, Study Finds
Development time is the same for cancer drugs cleared under subpart H and under the regular approval pathway, according to a study in the Journal of Clinical Oncology. Article calls attention to idea that cancer drugs may need new, more favorable FDA policies on surrogate markers.
Accelerated Approval Does Not Speed Oncologics To Market, Study Finds
Development time is the same for cancer drugs cleared under subpart H and under the regular approval pathway, according to a study in the Journal of Clinical Oncology. Article calls attention to idea that cancer drugs may need new, more favorable FDA policies on surrogate markers.
No FDAer For Commissioner, Interim or Otherwise, Rep. Stupak Urges Obama
The pharmaceutical industry has an unusual new ally in its effort to achieve some of its goals during the presidential transition: Rep. Bart Stupak, D-Mich